The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple times and, according to an analyst, will lead to a restructuring of the ...
U.K.-based biotechnology company F2G has raised $100 million to complete late-stage testing of a new kind of antifungal treatment and bring it back to U.S. regulators’ desks after they rejected it ...